Fiona (for Roger Song)'s questions to Altimmune Inc (ALT) leadership • Q4 2024
Question
Fiona from Jefferies inquired about the upcoming R&D Day, asking if details on preclinical data for the two new indications would be shared and whether the Phase II trials for these indications would commence simultaneously.
Answer
CEO Dr. Vipin Garg confirmed that Altimmune will provide a comprehensive overview of the two new indications at the R&D Day, including presentations from Key Opinion Leaders (KOLs) and details on the planned Phase II programs.